DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Wieacker-Wolff syndrome — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleWieacker-Wolff syndrome maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for wieacker-wolff syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cyclin H (CCNH) — CCNH is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3s,4sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8P77 · 1.8 Å · ligand (3S,4S)-4-[[[7-[(phenylmethyl)amino]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol (I73). Experimental structure, not a prediction.
What the evidence adds up to
The 1987 linkage study concerns Wieacker-Wolff syndrome, an X-linked recessive disorder characterised by congenital contractures, progressive neuropathic muscle atrophy involving cranial nerves (oculomotor apraxia, dyspraxia of face and tongue muscles), and mental retardation. In a single large family, the syndrome locus showed close linkage to the DNA segment DXYS1 in proximal Xq, with a maximum lod score of 3.225 at a recombination fraction of 0.0. No drug or treatment was tested in that study.
Two later abstracts discuss Wolff-Parkinson-White syndrome, a different condition with a similar name. In a 2019 case report, an elderly patient with paroxysmal supraventricular tachycardia and atrial fibrillation in the context of Wolff-Parkinson-White syndrome was treated with bisoprolol and flecainide. The authors note that atrioventricular nodal blockers can precipitate ventricular fibrillation and should not be used in this setting, but they do not report any outcome data for the bisoprolol and flecainide combination beyond presenting the case.
A 2015 study of 60 patients with Wolff-Parkinson-White syndrome (41 men, 19 women) found that radiofrequency catheter ablation was effective in 93.3% of patients. Compared with 28 healthy controls, patients before ablation had significantly reduced physical and mental health scores on the MOS 36-Item Short-Form Health Survey. At 3 months after ablation, physical health improved by 13.5% and mental health by 17.2%; by 12 months, quality-of-life scores matched those of controls.
No abstract tests any drug for Wieacker-Wolff syndrome. The two Wolff-Parkinson-White abstracts are irrelevant to that condition. For Wieacker-Wolff syndrome, what remains missing is any clinical trial, any drug tested, any patient stratification, and any funding for treatment research.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 1987 · 25 citations
Close linkage of the Wieacker‐Wolff syndrome to the DNA segment DXYS1 in proximal Xq
AbstractAbstract Linkage studies with RFLPs were performed in a large family in which the Wieacker‐Wolff syndrome is segregating. In this new syndrome (McKusick, 1986, No.31458) patients have congenital contractures, progressive neuropathic muscle atrophy, involving also some cranial nerves with oculomotor apraxia and dyspraxia of the face and tongue muscles, and mental retardation. This is an X‐linked recessive syndrome. We found close linkage between the syndrome locus and the DNA segment DXYS1 (ẑ=3.225 at \documentclass{article}\pagestyle{empty}\begin{document}$ \mathord{\buildrel{\lower3pt\hbox{$\scriptscriptstyle\frown$}} \over \Theta } = 0.0 $\end{document} =0.0) in proximal Xq.
International Journal of Clinical Cardiology · 2019 · 3 citations · open access
Effects of Bisoprolol and Flecainide in an Elderly Patient with Paroxysmal Supraventricular Tachycardia and Atrial Fibrillation in Wolff-Parkinson-White Syndrome
AbstractWolff-Parkinson-White (WPW) syndrome can develop paroxysmal supraventricular tachycardia (PSVT) or/and paroxysmal atrial fibrillation (AF). AF in WPW syndrome is a potentially life-threatening arrhythmia. Radiofrequency catheter ablation is recommended in patients with AF in WPW syndrome. Atrioventricular nodal blockers can precipitate ventricular fibrillation and should not be used. We present patients with PSVT and AF in WPW syndrome who was treated with bisoprolol and flecainide.
International Journal of Biomedicine · 2015 · 0 citations · open access
Effect of Radiofrequency Catheter Ablation on Quality of Life in Patients with Wolff-Parkinson-White Syndrome
AbstractWolff-Parkinson-White (WPW) syndrome is one of several disorders of the conduction system of the heart that are commonly referred to as pre-excitation syndromes. As the syndrome significantly reduces the patients' quality of life (QoL), the purpose of the current study was to compare QoL scores in patients with WPW syndrome before and after a radiofrequency catheter ablation (RFA) procedure. To assess the patients' QoL, the MOS 36-Item Short-Form Health Survey was used. Immediate and long-term outcomes of radiofrequency catheter ablation were analyzed in 60 patients diagnosed with WPW syndrome, 41(68.3%) men and 19(31.7%) women. As compared with the controls (28 apparently healthy persons), patients with WPW syndrome before RFA experienced significant reduction in both physical and mental health components. RFA was found effective in 93.3% of patients with WPW syndrome. At 3 months after RFA, patients showed significant improvement in both physical (13.5%) and mental (17.2%) health components; at 12 months, QoL parameters reached those of the controls. (Int
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
